Pds Biotechnology Corp (PDSB) — 10-K Filings
All 10-K filings from Pds Biotechnology Corp. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
PDS Biotech Accelerates Clinical Pipeline with Phase 3 Initiation, FDA Talks
— Mar 30, 2026 Risk: high
PDS Biotechnology Corp (PDSB) is a clinical-stage immunotherapy company focused on cancer and infectious diseases, leveraging its Versamune T cell activator and -
PDS Biotechnology Corp. Files 2023 Annual Report on Form 10-K
— Mar 28, 2024 Risk: low
PDS Biotechnology Corp (PDSB) filed a Annual Report (10-K) with the SEC on March 28, 2024. PDS Biotechnology Corp. filed its 10-K report for the fiscal year end
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX